Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Lin, Lan-Hsi; Ghasemi, Mohammad; Burke, Sarah M.; Mavis, Cory K.; Nichols, Jenna R.; Torka, Pallawi; Mager, Donald E.; Hernandez-Ilizaliturri, Francisco J.; Goey, Andrew K. L.

doi:10.1007/s11523-023-00992-4

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Typically, these techniques are integrated with PK modelling, allowing for the characterization of the dose–exposure–response relationship, which is a crucial step in optimizing the drug efficacy and minimizing adverse effects, ultimately leading to improved therapeutic outcomes. Lin et al [ 94 ] developed a population-based PKPD model for carfilzomib in adult patients with relapsed/refractory diffuse large B-cell lymphoma using the NONMEM ® software (version 7.4.1). Such studies contribute to ongoing research aiming to identify characteristics of patients who benefit from this specific treatment.…”

Section: Pharmacometrics Tools: Significance and Challenges In Precis...mentioning

confidence: 99%

Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare

Marques,

Costa,

Pereira

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

The landscape of medical treatments is undergoing a transformative shift. Precision medicine has ushered in a revolutionary era in healthcare by individualizing diagnostics and treatments according to each patient’s uniquely evolving health status. This groundbreaking method of tailoring disease prevention and treatment considers individual variations in genes, environments, and lifestyles. The goal of precision medicine is to target the “five rights”: the right patient, the right drug, the right time, the right dose, and the right route. In this pursuit, in silico techniques have emerged as an anchor, driving precision medicine forward and making this a realistic and promising avenue for personalized therapies. With the advancements in high-throughput DNA sequencing technologies, genomic data, including genetic variants and their interactions with each other and the environment, can be incorporated into clinical decision-making. Pharmacometrics, gathering pharmacokinetic (PK) and pharmacodynamic (PD) data, and mathematical models further contribute to drug optimization, drug behavior prediction, and drug–drug interaction identification. Digital health, wearables, and computational tools offer continuous monitoring and real-time data collection, enabling treatment adjustments. Furthermore, the incorporation of extensive datasets in computational tools, such as electronic health records (EHRs) and omics data, is also another pathway to acquire meaningful information in this field. Although they are fairly new, machine learning (ML) algorithms and artificial intelligence (AI) techniques are also resources researchers use to analyze big data and develop predictive models. This review explores the interplay of these multiple in silico approaches in advancing precision medicine and fostering individual healthcare. Despite intrinsic challenges, such as ethical considerations, data protection, and the need for more comprehensive research, this marks a new era of patient-centered healthcare. Innovative in silico techniques hold the potential to reshape the future of medicine for generations to come.

show abstract

Section: Pharmacometrics Tools: Significance and Challenges In Precis...mentioning

confidence: 99%

Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare

Marques,

Costa,

Pereira

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

Pharmacokinetics–Pharmacodynamics Modeling for Evaluating Drug–Drug Interactions in Polypharmacy: Development and Challenges

Zhao,

Huang,

et al. 2024

Clin Pharmacokinet

View full text Add to dashboard Cite

Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Cited by 2 publications

References 24 publications

Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare

Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare

Pharmacokinetics–Pharmacodynamics Modeling for Evaluating Drug–Drug Interactions in Polypharmacy: Development and Challenges

Contact Info

Product

Resources

About